April 29 (SeeNews) - North Macedonia's drug maker Alkaloid [MSE:ALK] said on Monday that its consolidated net profit grew by an annual 9% to 479.5 million denars ($8.3 million/7.8 million euro) in the first quarter of 2024.
Sales revenue rose 13% year-on-year to 4.9 billion denars in the January-March period, Alkaloid said in an interim financial statement filed with the Skopje bourse.
Sales abroad increased by 14% to 3.6 billion denars, while domestic sales added 11% to 1.3 billion denars.
The cost of goods sold was 10% higher on the year at 2.8 billion denars in the review period.
Alkaloid's shares traded at an average price of 20,200 denars on the stock exchange in Skopje on Friday, according to the most recent data available from the bourse.
Alkaloid has two subsidiaries in North Macedonia and 19 subsidiaries and two representative offices abroad - in Serbia, Montenegro, Kosovo, Albania, Bosnia and Herzegovina, Croatia, Slovenia, Romania, Switzerland, Bulgaria, Turkey, Ukraine, Russia, the U.S. and the UK.
(1 euro = 61.54 denars)